TRT claims on TikTok: separating hype from hypogonadism science

What did @newyorkendocrinology actually say?

The creator, presenting as an endocrinologist, walked through the main testosterone delivery routes: transdermal (gels, creams, patches applied daily), intramuscular and subcutaneous injectables, and oral formulations. She noted that intramuscular injections run weekly or every two weeks, while subcutaneous is weekly. She compared the subcutaneous pen device to a "sambagavian gyro" (almost certainly semaglutide, as in Ozempic), emphasizing the smaller needle. Then she covered monitoring: check testosterone four to six weeks after starting treatment, two hours post-application for transdermal, the day before or morning of the next injection for injectables, and two to four hours post-dose for oral formulations.

The video is tightly focused and clinically oriented. No miracle claims, no before-and-after promises. That alone puts it above most TRT content on TikTok.

Does the science back this up?

Mostly, yes. The delivery method breakdown and monitoring timing guidance align with established clinical practice, though a few specifics are imprecise enough to matter in a real patient's life.

The American Urological Association and Endocrine Society guidelines both confirm the four delivery categories she named: transdermal, injectable, oral, and (not mentioned here) intranasal and pellets. The monitoring window of four to six weeks is supported in practice guidelines, though some protocols push to eight to twelve weeks before dose adjustment (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism).

Her transdermal monitoring window of "at least two hours" post-application reflects real pharmacokinetic data. A 2020 study in Andrology (Wang et al.) showed peak serum testosterone from topical gel occurs roughly two to eight hours after application, so two hours is technically within range but may catch levels still rising. Four to six hours is the more commonly cited target in clinical pharmacokinetic literature for AndroGel and similar products.

The injectable trough timing guidance is solid. Checking the day before or morning of the next injection captures trough levels, which is exactly what prescribers need to avoid over- or under-dosing. This matches standard practice.

What did they get wrong (or right)?

The subcutaneous comparison to a semaglutide pen is colorful but imprecise. Subcutaneous testosterone is not universally delivered via auto-injector pen. Xyosted (testosterone enanthate subcutaneous) does come in a prefilled autoinjector, but many subcutaneous protocols use a standard insulin syringe drawn from a vial. Patients watching this may expect a specific device that their prescriber doesn't use.

The claim that intramuscular injections use a "large long needle" is a mild overcorrection. Most IM testosterone injections use a 1 to 1.5 inch, 22 to 23 gauge needle, which is not particularly large. Framing it as dramatically different from subcutaneous may discourage patients from choosing IM when it's clinically appropriate for them.

The oral testosterone mention is accurate in that oral formulations exist. Jatenzo (testosterone undecanoate) is FDA-approved. But she gives it almost no airtime, which is fair given that it carries a boxed warning for blood pressure increases and is rarely a first-line choice. No complaint there.

What she got right: the monitoring framework is clinically sound. Checking trough for injectables and post-absorption peak for transdermal and oral is exactly what guidelines recommend. That's more precision than most TRT content delivers.

What should you actually know?

If you are starting TRT or already on it, monitoring timing is not optional or approximate. Checking testosterone at the wrong time in your dosing cycle can produce a number that leads your prescriber to adjust a dose that did not need adjusting. That has real consequences: too high and you risk erythrocytosis (elevated red blood cell count), which is one of the more serious TRT side effects documented in long-term cohort data (Bachman et al., 2010, Journal of Clinical Endocrinology and Metabolism). Too low an adjustment and symptoms return.

The four-to-six-week check she mentions is a minimum. Many endocrinologists and urologists also check hematocrit, PSA, and lipids at that interval, not just testosterone. A testosterone number in isolation tells only part of the story.

Subcutaneous testosterone has genuinely grown in clinical use. A 2017 study in Urology (Ohl et al.) found subcutaneous testosterone enanthate produced stable serum levels with good tolerability, giving it a legitimate place alongside IM. The smaller needle does matter to adherence for some patients. That point stands.

• Transdermal peak absorption typically occurs two to eight hours post-application, not simply "at least two hours."
• Injectable trough testing, the day before or morning of next injection, is the clinical standard for accurate dosing assessment.
• Subcutaneous testosterone is not always pen-delivered. Confirm your device type with your prescriber.
• Oral testosterone (Jatenzo) carries an FDA boxed warning for hypertension. It is not interchangeable with other forms.
• Four to six weeks is an appropriate first check, but a complete panel includes hematocrit and PSA, not just testosterone levels.